Validation of SeptiCyte RAPID to discriminate sepsis from non-infectious systemic inflammation

Robert Balk [1], Annette M. Esper [2], Greg S. Martin [2], Russell R. Miller III [3], Bert K. Lopansri [4,5], John P. Burke [4,5], Mitchell Levy [6], Steven Opal [6], Richard E. Rothman [7], Franco R. D'Alessio [7], Venkataramana K. Sidhaye [7], Neil R. Aggarwal[8], Jared A. Greenberg [1], Mark Yoder [1], Gourang Patel [1], Emily Gilbert [9], Jorge P. Parada [9], Majid Afshar [10], Jordan A. Kempker [2], Tom van der Poll [11], Marcus J. Schultz [11], Brendon P. Scicluna [12], Peter M.C. Klein Klouwenberg [13], Janice Liebler [14], Emily Blodget [14], Santhi Kumar [14], Krupa Navalkar [15], Thomas D. Yager [15], Dayle Sampson [15], James T. Kirk [15], Silvia Cermelli [15], Roy F. Davis [15], and Richard B. Brandon [15]

[1]Rush Medical College and Rush University Medical Center, Chicago, Illinois;
[2]Grady Memorial Hospital and Emory University School of Medicine, Atlanta, Georgia;
[3]FirstHealth of the Carolinas, Pinehurst, North Carolina;
[4]Intermountain Medical Center, Murray, Utah;
[5]University of Utah School of Medicine, Salt Lake City, Utah;
[6]Brown University, Providence, Rhode Island;
[7]Johns Hopkins University School of Medicine, Baltimore, Maryland;
[8]Anschutz Medical Campus, University of Colorado, Denver, Colorado;
[9]Loyola University Medical Center, Maywood, Illinois;
[10]University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin;
[11]Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;
[12]Centre for Molecular Medicine and Biobanking, University of Malta, Malta; and Department of Applied Biomedical Science, Faculty of Health Sciences, Mater Dei hospital, University of Malta, Malta
[13]Isala Hospital, Zwolle, the Netherlands;
[14]Keck Hospital of University of Southern California (USC); and Los Angeles County and USC Medical Center;
[15]Immunexpress Inc., Seattle, Washington

Corresponding Author, to whom requests for reprints and correspondence should be addressed: Dr. Robert Balk, Rush Medical College and Rush University Medical Center, Chicago, Illinois.

This article has Supplementary Information, which is accessible online and linked to the article.

Running title: Validation of SeptiCyte RAPID for sepsis vs. SIRS

Author Contributions:
Conceptualization: RFD, SC, RBB, DS, TDY
Methodology: RFD, SC, DS, TDY, KN
Investigation: RB, AME, GSM, RRMIII, BKL, JPB, ML, SO, RER, FRDA, VKS, NRA, JAG, MY, GP, EG, MA, FRDA, JPP, JAK, TvdP, MJS, BPS, PMCKK, JL, EB, SK
Supervision: SC, RFD, RB, AME, GSM, RRMIII, BKL,TvdP, JL, EG
Data Curation & Review: SC, DS, KN
Clinical Assessment: SO, RER, ML
Custom software: DS, KN
Visualization: DS, KN, TDY
Formal analysis: DS, KN, TDY, SC
Writing: initial & successive drafts: TDY, RBB, RFD
Writing: review and edits: TDY, RBB, RFD, SC, JTK, RB, GM, JAK, BPS, TvdP, PMCKK
Funding acquisition: Immunexpress, Inc.

Sources of Support: This study was supported by Immunexpress Inc.

Best Descriptor: CRITICAL CARE, 4.12 Sepsis/Multiple Organ Failure

WORD COUNT:
BACKGROUND 347 words
METHODS 841 words
RESULTS 1,329 words
DISCUSSION 1,343 words
CONCLUSIONS 37 words
ACKNOWLEDGEMENTS 52 words

TOTAL 3,949 words

Abstract

Background: SeptiCyte RAPID is a molecular test for distinguishing sepsis from non-infectious systemic inflammation. The objective of this study was the clinical validation of SeptiCyte RAPID, based on testing retrospective (banked) and prospectively collected patient samples.

Methods: Testing retrospective (banked) and prospective samples from adult patients in ICU either having systemic inflammatory response syndrome (SIRS) or suspected of sepsis. Test results were compared to a "gold standard" of clinical evaluation by a blinded three physician external panel.

Results: The cartridge-based SeptiCyte RAPID assay accepts a PAXgene blood RNA sample and provides sample-to-answer processing in ~1 hour. The test output (SeptiScore, range 0-15) falls into four interpretation bands, with higher scores indicating higher probabilities of sepsis. SeptiCyte RAPID performance is comparable to that for SeptiCyte LAB, with Area Under the ROC Curve (AUC) ranging from 0.82 – 0.85, negative predictive value 0.91 (sensitivity 0.94) for SeptiScores between 0.1 and 5.0 (Band 1, lowest risk of sepsis), and positive predictive value 0.81 (specificity 0.90) for SeptiScores between 7.4 and 15 (Band 4, highest risk of sepsis). For all blood culture confirmed sepsis cases, SeptiCyte RAPID indicated an elevated risk of sepsis with 34/38 (90%) of scores falling in bands 3 or 4. In multivariable analysis, SeptiScore was the most important variable for sepsis diagnosis. A likelihood ratio method was developed to estimate the post-test probability of sepsis for individual patients, when combining the SeptiScore with additional clinical parameters.

Conclusions: This study validates SeptiCyte RAPID for differentiating patients with sepsis vs. SIRS, on the first day of ICU admission.

Trial Registration: NCT01905033 (MARS), NCT02127502 (VENUS), NCT05469048 (NEPTUNE, retrospectively registered) at clinicaltrials.gov.

Keywords: sepsis, diagnosis, host response, SIRS, sepsis scoring systems

ABSTRACT WORD COUNT: 277 words

Background

Sepsis is an important and expensive global health problem with high morbidity and mortality [1]. According to the World Health Organization, more than 11 million people die from sepsis worldwide annually, comprising more than the deaths caused by all cancers combined [2]. Sepsis is the leading cause of death in U.S. hospitals is ranked as the most expensive disease state to manage for admitted patients [3], with total annual costs of treatment and rehabilitation estimated at $62 billion [4]. Before the COVID-19 pandemic, at least 1.7 million adults in the United States developed sepsis annually [5]. During the pandemic, this problem was greatly exacerbated, as most COVID-19 deaths are due to viral and/or bacterial sepsis [6]. Up to 20% of all deaths worldwide can be attributed to sepsis on an annual basis [1].

Early identification of sepsis and implementation of treatment bundles have been shown to improve outcomes for sepsis patients [7]. However, early identification of sepsis can be difficult for many reasons. In the early stages of the disease, patients present with clinical signs that are common to many other non-infectious conditions [8]. Furthermore, sepsis does not have a diagnostic gold standard since blood cultures lack timeliness [9] and are negative in 30-50% of retrospectively diagnosed cases [10,11]. In addition, unnecessary administration of broad-spectrum antibiotic therapy for presumed sepsis may adversely contribute to the growing problem of multidrug resistant organisms and carries the risk of adverse drug reactions [12].

We previously reported on the development and validation of a diagnostic assay (SeptiCyte LAB) to differentiate patients with sepsis from those with non-infectious systemic inflammation, providing a probability of sepsis based on measurement of four host immune response

biomarkers [13, 14]. Here we present data on the clinical validation of SeptiCyte RAPID, a simplified and improved cartridge-based version of this assay. SeptiCyte RAPID assay addresses a clinical need for more rapid and accurate differentiation of sepsis from non-infectious systemic inflammatory response syndrome (SIRS) within a clinically actionable (~1 hour) time frame. Some of these results have been presented earlier in the form of an abstract [15].

Methods

Gene expression signature

The SeptiCyte RAPID signature measures the relative expression levels of two immune-related mRNAs, PLAC8 (Placenta-associated 8) and PLA2G7 (Phospholipase A2 Group 7). The signature, which has two fewer biomarkers than SeptiCyte LAB [14], was discovered using a purely bioinformatic approach, as described previously [13]. PLAC8 is reportedly an interferon inducible gene and is expressed in a variety of tissues rich in immune cells (e.g. whole blood, spleen, lymph node, colon), and in sepsis is up-regulated across a broad range of different peripheral blood cell types including plasmacytoid dendritic and natural killer cells. PLA2G7 encodes the protein platelet-activating factor (PAF) acetylhydrolase, a secreted enzyme primarily produced by macrophages that catalyzes the degradation of PAF and hydrolyses the oxidized short chain phospholipids of low-density lipoproteins (LDL), thereby releasing pro-inflammatory mediators (lysophospholipids and oxidized fatty acids). Further discussion and literature references are provided in the Supplementary Information, Section 1.

Study cohorts

Clinical validation of SeptiCyte RAPID used PAXgene blood RNA samples from retrospective (N=356) and prospective (N=63) patient cohorts.The retrospective cohort was drawn from the observational MARS and VENUS trials (www.clinicaltrials.gov NCT01905033 and NCT02127502) which have been previously described [14]. The retrospective cohort comprised 80% of the 447 patients used for the 510(k) clearance of SeptiCyte LAB for which duplicate banked PAXgene blood RNA samples remained available.

The prospective cohort consisted of 63 critically ill adult subjects enrolled in an observational trial (NEPTUNE, www.clinicaltrials.gov NCT05469048) between the dates May 26, 2020 - April 25, 2021 at Emory University / Grady Memorial Hospital (Atlanta GA), Rush University Medical Center (Chicago IL) and University of Southern California Medical Center (with 2 separate sites, Keck Hospital of USC, and LAC+USC Medical Center, in Los Angeles CA). The study protocol was approved by each institutional review board (see below). All patients (or legally authorized representatives) provided signed informed consent.

Subjects were considered for inclusion if adult (≥18 years old), exhibited two or more SIRS criteria, and received an ICU admission order. Subjects were “suspected of sepsis” if microbiological tests were ordered within 24 hours of the ICU admission order. Subjects were excluded if therapeutic antibiotic treatment was initiated >24 hours before ICU admission order. As much as possible, enrollments were consecutive; however, during the COVID-19 pandemic, screening did not happen every day, and initial consenting sometimes resulted in later refusal to participate. PAXgene blood samples were collected within 24 hours of ICU admission order, and

run fresh, in real time on Idylla instruments installed at the sites. Clinical data were collected on case report forms as described previously [14].

Ethics approvals for the MARS and VENUS trials (retrospective cohort) were previously referenced [14]. Ethics approvals for the NEPTUNE trial (prospective cohort) are as follows: # IRB00115400 (Emory University); # 00-115400 (Grady Memorial Hospital); # 19101603-IRB01 (Rush University Medical Center), and # HS-19-0884-CR001 (University of Southern California Medical Center). The retrospective and prospective trials comply with the CONSORT checklist, and a CONSORT flow diagram is provided in the Supplementary Information, Section 2.

Reference method and calculations

Clinical performance of SeptiCyte RAPID was determined by comparison to a 'gold standard' of clinical adjudication. The adjudication process, termed retrospective physician diagnosis (RPD), consisted of clinical evaluations by an external three-member panel of experienced physicians not involved in the care of the patients. For each patient, a chart review was conducted independently by each panel member, leading to a three-way classification (sepsis, SIRS or indeterminate) in accordance with the Sepsis-2 definition [16]. The vote tally for each patient was either unanimous, consensus (2 of 3), or indeterminate. There were 41/419 (9.8%) indeterminates, which were then reanalyzed and forced into either sepsis or SIRS categories by a second RPD. The Sepsis-2 definition was used because many of the patients were recruited before the Sepsis-3 definition became available, and because the RAPID SeptiScore does not correlate strongly with organ dysfunction. Additional details are provided in reference [14] and the Supplementary Information, Sections 3-4.

Sepsis probability as a function of RAPID SeptiScore was calculated by a “sliding window” approach (Supplementary Information, Section 7).The continuous range of sepsis probabilities was also parsed into four bands, with higher sepsis probabilities correlating with higher SeptiScores. Band boundaries were pre-defined, based on an independent set of 195 clinical samples from the MARS consortium. These samples gave 90% sensitivity for binarization at the Band 1/2 cutoff (SeptiScore 4.95) and 80% specificity for binarization at the Band 3/4 cutoff (SeptiScore 7.45) using the MARS clinical adjudications as Ground Truth values. The intermediate zone between the Band 1/2 and Band 3/4 cutoffs was divided in half to define the Band 2/3 cutoff (SeptiScore 6.15). For the final retrospective and prospective datasets, sensitivity and negative predictive value (NPV) for Band 1 were calculated using a binary split of the data at the 4.95 boundary. Similarly, specificity and positive predictive value (PPV) for Band 4 were calculated using a binary split of the data at the 7.45 boundary. Additional statistical methods for data analyses, including combining the SeptiScore with other clinical variables, are described in the Supplementary Information, Sections 7-12.

Results

Demographic and clinical characteristics

The population demographics from the combined retrospective and prospective clinical validation cohorts (n=419) are presented in **Table 1**. Sepsis, SIRS or indeterminate diagnoses were assigned by consensus RPD. When compared to patients with SIRS, patients adjudicated as septic tended to be older ($p = 0.016$). There were no significant differences by sex or race/ethnicity. Patients originated from a variety of locations within the hospital systems in our

study. Patients coming from hospital wards exhibited a higher proportion of sepsis relative to patients coming from the ED ($p = 0.0026$), post-anesthesia unit / post-operating room ($p < 0.00001$), or ICU / cardiac care unit ($p = 0.024$).

Clinical characteristics of the study population are presented in **Table 2.** Of particular note are culture results of high statistical significance: positive blood cultures, positive urine cultures, and dual-positive cultures (blood+urine) were very highly associated with RPD diagnoses of sepsis, as opposed to SIRS, with p-values of 2.7×10^{-12}, 3.1×10^{-6}, and 9.0×10^{-4} respectively. A breakdown of the culture-confirmed pathogens for the sepsis cases is presented in the Supplementary Information, Sections 5-6.

SeptiCyte RAPID performance: primary analyses

Test and device description: SeptiCyte RAPID is an *in-vitro* diagnostic test for simultaneous amplification and detection of two RNA transcripts (PLA2G7 and PLAC8) in human blood samples.The test is run on a near-to-patient platform, Idylla, manufactured by Biocartis NV (Mechelen, Belgium). The SeptiCyte RAPID test is performed by pipetting 0.9 mL of PAXgene-stabilized blood (corresponding to 0.24 mL of drawn blood) into a custom cartridge which performs all assay steps including sample extraction/purification and RT-qPCR for the detection and relative quantification of the PLAC8 and PLA2G7 mRNA targets. Test results are presented automatically through a software-generated report which includes a quantitative probability score (SeptiScore, range 0-15), calculated by combining the RT-qPCR Cq values measured for PLAC8 and PLA2G7. The test has a hands-on time of ~2 min and a turnaround time of ~1 hour.

Comparison to predicate: **Figure 1** shows a strong correlation of SeptiScores between SeptiCyte LAB and SeptiCyte RAPID, based upon the 356 clinical samples from the

retrospective cohort run on both platforms (Pearson's sample correlation coefficient r = 0.88). In serial dilution experiments, SeptiCyte RAPID scores were verified to be independent of the white blood cell (WBC) count across an input range of 25 to 25,000 WBC/µl.

ROC curve analyses: Receiver operating characteristic (ROC) curve analyses were performed on samples from the retrospective cohort (**Figure 2A**), the prospective cohort (**Figure 2B**), and the combined retrospective + prospective cohorts (**Figure 2C**). Performance estimates for the retrospective cohort ranged from AUC 0.82-0.85 (depending upon RPD method) and were statistically indistinguishable both from each other, and from SeptiCyte LAB AUC values [14]. Performance estimates for the prospective cohort ranged from AUC 0.86-0.95 (depending upon RPD method) and again were statistically indistinguishable from each other.

A statistical comparison of the ROC curves from Figure 2A (retrospective cohort) vs. 2B (prospective cohort) showed an absence of significant differences, except for the unanimous RPD curves in the two figures, for which deLong's test gave p = 0.013. For a binary discrimination of sepsis versus SIRS in the combined retrospective + prospective dataset, using consensus RPD as comparator, the relationship between threshold, sensitivity, and specificity (derived from the appropriate ROC curve) is shown in **Figure 2D**.

Sepsis probability distributions: The distribution of SeptiScores for septic patients falls above that for patients with SIRS (**Figure 3A**). A sliding window analysis (**Figure 3B**) is used to calculate the probability of sepsis as a function of SeptiScore (**Figure 3C**). Patients with higher SeptiScores have higher probabilities of sepsis. To assist in interpretation and downstream

clinical decision making, we also report SeptiScores in terms of four probability bands (**Figure 3D**) as for the predicate, SeptiCyte LAB. The band boundaries were pre-set at 4.95, 6.15 and 7.45 (see Methods section above), giving high sensitivity for Band 1 and high specificity for Band 4. A strong correlation was found between the banding schemes for SeptiCyte LAB and SeptiCyte RAPID (**Figure 4**), which holds true regardless of whether the retrospective, prospective, or combined cohorts are examined for SeptiCyte RAPID. **Table 3** presents SeptiScores for the complete (retrospective + prospective) cohort, for the retrospective and prospective cohorts separately, and also for SeptiCyte LAB, parsed into the four probability bands. Assignment of sepsis or SIRS was by consensus RPD. The probability of and likelihood ratio for sepsis both increase with increasing SeptiScore.

SeptiCyte RAPID clinical performance: secondary analyses

Chi-squared analyses (**Table 4**) indicated that, after sorting patients into the four SeptiScore bands, no significant differences were found with respect to baseline demographic criteria (sex, age, race or ethnicity). Positive culture results (blood, urine, and blood/urine double positive) were more predominant in the higher SeptiScore bands (especially Band 4), with chi-squared analyses giving p-values of 7.2×10^{-6}, 0.023 and 0.005 for the observed distributions of these positive results in Band 4 vs. pooled Bands 1+2+3. Of the positive results from blood, urine, and blood+urine culture, the percentages falling in Band 4 were 63%, 52% and 73% respectively, and the percentages falling in either Band 3 or Band 4 were 83%, 64% and 82% respectively. Of the 41 patients with blood culture positive results, only one had a SeptiScore in Band 1. This patient was diagnosed as SIRS by RPD, with the blood culture result (coagulase negative Staphylococcus) being considered a probable contaminant.

Multivariable analysis: We asked whether SeptiCyte RAPID can provide diagnostic clinical utility for discriminating between sepsis and SIRS patients, beyond that provided by other clinical variables and laboratory assessments available on the first day of ICU admission. Fourteen variables in addition to SeptiCyte RAPID were examined (see Supplementary Information, Sections 9-10). We evaluated all 32,767 possible combinations of the fifteen variables, and performance was assessed by AUC against consensus RPD. Procalcitonin was included in this analysis, as well as lactate which is a commonly used and rapidly assessed variable to determine which patients should receive sepsis treatment bundles [17, 18]. **Figure 5A** shows the results of the multivariable analysis for the combined retrospective and prospective cohorts, while **Figure 5B** shows the comparable results for just the prospective cohort. The AUC distributions for the prospective cohort appear somewhat high compared to those for the full patient cohort, possibly because of overfitting (the prospective cohort has only 54 patients with SIRS or sepsis by consensus RPD, as compared to 154 in the full patient cohort). With respect to individual variables, SeptiScore was found to rank highest by AUC. When combinations of clinical variables were considered, those containing SeptiScore were found to have higher AUCs than all combinations lacking SeptiScore.

Sepsis probability adjustments: The preceding multivariable analysis suggests that SeptiCyte RAPID might be combined with other clinical variables to boost the overall performance at discriminating between sepsis and SIRS (see the red AUC distributions in Figures 5A, 5B). Therefore, we investigated which additional clinical variables could be used in combination with SeptiCyte RAPID to improve diagnostic performance (post-test probability of sepsis).

Additional clinical variables of importance were identified through a machine learning (Random Forest) analysis of our clinical validation data (Supplementary Information, Section 11). Assurance of the results was gained through a literature search and by consulting with experienced clinicians. We then combined the identified significant variables in a sequential likelihood ratio analysis [19, 20]. Details of the analysis are provided in Supplementary Information, Section 12. The pre-test versus post-test sepsis probabilities for six selected patients are shown in **Figure 6** and **Table 5**. Three of the patients were diagnosed with SIRS, and had SeptiScores in Bands 1-2. The other three patients were diagnosed with sepsis, and had SeptiScores in Band 4. Through combining the SeptiScores with other clinical variables (PCT, Temp max, WBC min, Respiratory Rate max, Mean Arterial Pressure min, and # (SIRS characteristics), the post-test probability of sepsis was further decreased for the SIRS patients, while for the septic patients the post-test probability of sepsis was further increased.

Discussion

We have presented data validating the use of SeptiCyte RAPID for differentiating sepsis from SIRS in critically ill adult patients, within a clinically actionable time frame. Patients in this study came from the ED, post-anesthesia unit, post-operating rooms and wards, and were tested in the ICU. For the full (retrospective + prospective) cohort, diagnostic performance of SeptiCyte RAPID was equivalent to that previously reported for the predicate device, SeptiCyte LAB [14] with AUC ranging from 0.81 – 0.84 depending upon comparator method (RPD). Using consensus RPD as reference, patients with Band 1 SeptiScores had an estimated 9% probability of sepsis, while those with Band 4 SeptiScores had a much higher estimated probability of sepsis (~81%). For the prospective cohort, diagnostic

performance of SeptiCyte RAPID based on AUC was higher than for the full cohort, ranging from 0.86 – 0.98 depending upon RPD method. With consensus RPD, patients with SeptiScores in Band 1 were estimated to have a ~0% average probability of sepsis, while patients with SeptiScores in Band 4 were estimated to have an average sepsis probability of ~83%.

We note that the comparator method (RPD) is imperfect. In our complete (n=419) validation dataset, three expert clinicians failed to reach either a unanimous or consensus diagnosis for 41/419 (9.8%) of patients. The use of an imperfect comparator sets an upper limit to the measurable diagnostic performance of a new test [21]. This observation mirrors the real-life reality that the diagnosis of sepsis is often difficult, even with a retrospective chart review that includes all the clinical data and outcome information.

In a multivariable analysis, we examined all possible combinations of SeptiScore and up to 14 additional clinical or laboratory variables, including lactate and PCT. We found that SeptiScore alone had greater performance than any combination of variables without SeptiScore, for differentiating sepsis vs. SIRS (Figure 5). However, our analysis also indicated it should be possible to moderately boost the performance of SeptiCyte RAPID by combining the SeptiScore with other clinical parameters. Accordingly, we developed a likelihood ratio approach for updating post-test sepsis probabilities, through the sequential application of likelihood ratios calculated with additional clinical parameters (Figure 6 and Online Data Supplement, Section 12). We believe this approach may have utility for patients with intermediate SeptiScore values falling in Band 2 or Band 3.

In 2017 the Surviving Sepsis Campaign (SSC) published updated sepsis management guidelines with the objective of guiding and improving the care of sepsis [22]. These guidelines

and the introduction of the sepsis core measures by the United States Centers for Medicare and Medicaid Services inadvertently led to encouraging physicians to initiate early broad-spectrum antibiotics in patients who were at low risk for sepsis [23]. The recent updated Surviving Sepsis Campaign guidelines (2021) have attempted to address this problem by dividing the patients into three groups (low, intermediate, and high) based on sepsis probability, and have recommended appropriate evaluation and treatment of these groups [24]. SeptiCyte RAPID aligns well with these guidelines, and could have a role in supporting their implementation, as well as contributing to their further refinement and evolution.

The SSC 'low sepsis probability' group has, under previous guidelines, been treated early resulting in poor antibiotic stewardship. The new guidelines recommend deferring antibiotics, and monitoring and evaluate for other etiologies that may underlie the presenting symptoms. A SeptiScore <5 (Band 1) with a sensitivity of 0.94 in this group of patients could potentially support the deferring of antibiotics, thereby facilitating antibiotic and diagnostic stewardship.

For patients falling in the SSC 'intermediate sepsis probability (without shock)' group, the SSC recommendation is a rapid assessment of infectious versus non-infectious cause of the illness. Septicyte RAPID, with a one-hour turnaround time, rapidly differentiates infectious positive from infection negative systemic inflammation. The presence of elevated SeptiScores (Band 3 or Band 4) in this group would provide supporting evidence for infectious etiology, and for early antibiotic administration 24 to 48 hours before any positive microbiological results are available. The resulting SeptiScore turnaround time of ~1 hour would also aid in meeting the recommended 3-hour initiation of antibiotics for this group.

Per the SSC guidelines, those patients in the 'high sepsis probability' group, differentiated by the presence of shock, should appropriately be treated within 1 hour of recognition. SeptiScores in Band 4 (>7.5) in this patient group, with specificity 0.9 or greater, would provide evidence for a high probability of sepsis and the continuation of antibiotics.

We note several limitations to our study. We have focused only on adult patients within 24 hours of ICU admission, so generalization to other patient cohorts not been established. To avoid potential confounding effects, the study excluded subjects who received therapeutic antibiotic treatment > 24 hours before ICU admission, which could comprise a significant fraction of patients transferred from the floor to ICU. Most of the study was based on re-analysis of banked samples (356/419 = 85%), while only 63/419 (15%) were prospectively collected. We have not conducted serial sampling to measure variation in SeptiCyte RAPID scores as patients move into, through, and out of ICU. We have, however, previously reported strong diagnostic performance of SeptiCyte LAB in children [25] and the high correlation between SeptiCyte LAB and SeptiCyte RAPID (Figure 1) suggests that an equivalently strong performance in children will be found for SeptiCyte RAPID.

SeptiScores falling in Bands 2 or 3 do not, by themselves, provide definitive conclusions (i.e. very high or low probabilities) regarding the absence or presence of sepsis. For SeptiScores in this range, interpretation would be enhanced by combining the readings with data from other clinical variables, to adjust the post-test sepsis probabilities (see Table 5 and Figure 6).

During the discovery and initial validation of the PLAC8 and PLA2G7 biomarkers used in SeptiCyte RAPID [13, 14], patients with a broad range of co-morbidities were examined, including septic patients with confirmed bacterial, viral, fungal infections and malignancies, and

non-septic patients with non-infectious systemic inflammation of varying etiologies. The validation cohort also included use of a broad range of prescribed medications such as immunosuppressants, anti-neoplastic drugs, antithrombotics, corticosteroids and statins. To our knowledge, SeptiCyte RAPID results are unaffected by these factors. However, there may be other specific conditions and treatments we have not yet examined, that could affect SeptiCyte RAPID performance.

We have shown that the Limit of Quantitation (LoQ) and Limit of Detection (LoD) of SeptiCyte RAPID is 25 WBC/μL of blood, and we have validated the test to an upper limit of 25,000 WBC/uL. This dynamic range of SeptiCyte RAPID is broad and extends well below and above the 4,000-11,000 WBC/uL normal reference range. However, we have not yet completed an evaluation of the assay on severely neutropenic patients. It also is possible that SeptiCyte RAPID scores might be skewed by selective leukopenias due to disease or medications, for example T cell depletion in HIV / AIDS. However, it is known from single cell sequencing studies that both PLAC8 and PLA2G7 are expressed across a range of different white cell types [26] which would mitigate the effect of a selective leukopenia.

The time between injecting a blood sample into the SeptiCyte RAPID cartridge and generating a test report is only ~1 hour. However, by the time patient blood is drawn and delivered e.g. to a STAT lab, the total time between blood draw and presentation of the test result to an attending clinician is likely to be 1.5-2 hours. Although this is longer than requirements to implement a 1-hour sepsis bundle, SeptiCyte RAPID would clearly provide timely information with respect to implementing a 3-hour sepsis bundle, which has been shown to have a low level of compliance in US hospitals [27, 28]. Compliance with a 3-hour sepsis bundle in patients with

severe sepsis and septic shock has been shown to improve survival and reduce overall costs [28]. SeptiCyte RAPID may thus provide clinical utility through helping to guide patient management decisions on the implementation and timing of sepsis bundles. Finally, the test may also enable a more appropriate selection or stratification of patients in clinical trials for sepsis-related pharmacological agents and therapeutic medical devices.

Conclusions

SeptiCyte RAPID addresses a clinical need for more rapid and accurate differentiation of sepsis from non-infectious systemic inflammation conditions by providing a probability of sepsis within a timeframe that would allow clinicians to take meaningful action.

Supplementary information

Supplementary information accompanies this paper.

Abbreviations

%A, Percent Agreement; ANOVA, Analysis of Variance; AUC, Area Under (Receiver Operator Characteristic) Curve; CAD, Coronary artery disease; CKD, Chronic kidney disease; CPAP, Continuous positive airway pressure; Cq, Quantification Cycle (for PCR); CRP, C-Reactive Protein; ED, Emergency Department; ICU, Intensive Care Unit; IQR, Interquartile Range; Ku,

Unweighted inter-observer kappa; Kw, Linearly weighted inter-observer kappa; LR, Likelihood Ratio; PCR, Polymerase Chain Reaction; PCT, Procalcitonin; PLA2G7, Phospholipase A2, Group VII; PLAC8, Placenta associated 8; ROC, Receiver Operator Characteristic (curve); RPD, Retrospective Physician Diagnosis; RT-qPCR, Reverse Transcription - Quantitative Polymerase Chain Reaction; SIRS, Systemic Inflammatory Response Syndrome; SSC, Surviving Sepsis Campaign; Tukey HSD, Tukey Honestly Significant Difference; WBC, White Blood Cell.

Acknowledgements

The authors thank the clinical study coordinators of the NEPTUNE study: Joyce D. Brown (Rush University), Liliacna Jara (University of Southern California), Leona Wells and Maya C. Whaley (Grady Memorial Hospital). The authors also thank the laboratory technical staff at each institution,at Reach Bio (Seattle WA), and at Biocartis (Mechelen, Belgium).

References

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–11.

2. Kempker JA, Martin GS. A global accounting of sepsis. Lancet. 2020;395:168-70.

3. Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Statistical Brief #204, published May, 2016. Rockville (MD): Agency for Healthcare Research and Quality (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK368492/

4. Paoli, C. J., Reynolds, M. A., Sinha, M., Gitlin, M. & Crouser, E. Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level. Crit Care Med. 2018;46:1889–97.

5. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al.; CDC Prevention Epicenter Program. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA. 2017;318:1241-9.

6. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11:4263.

7. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018; 44:925-8.

8. Liu VX, Bhimarao M, Greene JD, Manickam RN, Martinez A, Schuler A, et al. The Presentation, Pace, and Profile of Infection and Sepsis Patients Hospitalized Through the Emergency Department: An Exploratory Analysis. Critical Care Explor. 2021;3:e0344.

9. Lambregts, M. M. C., Bernards, A. T., Beek, M. T. van der, Visser, L. G. & Boer, M. G. de. Time to positivity of blood cultures supports early re-evaluation of empiric broad-spectrum antimicrobial therapy. PLOS One. 2019;14:e0208819.

10. Panday, RSN, Lammers, E. M. J., Alam, N. & Nanayakkara, P. W. B. An overview of positive cultures and clinical outcomes in septic patients: a sub-analysis of the Prehospital Antibiotics Against Sepsis (PHANTASi) trial. Crit Care. 2019;23:182

11. Panday RSN, Wang S, Ven PM van de, Hekker TAM, Alam N, Nanayakkara PWB. Evaluation of blood culture epidemiology and efficiency in a large European teaching hospital. PLOS One. 2019;14:e0214052.

12. Kadri, SS. Key takeaways from the U.S. CDC's 2019 antibiotic resistance threats report for frontline providers. Crit Care Med. 2020;48:939-45.

13. McHugh L, Seldon TA, Brandon RA, Kirk JT, Rapisarda A, Sutherland AJ, et al. A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts. PLOS Med. 2015;12:e1001916.

14. Miller RR 3rd, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, et al. Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. Am J Resp Crit Care Med. 2018;198:903-13.

15. Kirk J, Yager T, Cermelli S, Sampson D, Brandon R, Sillekens P, et al. Clinical performance of a rapid sepsis test on a near-patient molecular testing platform. Abstract # P481, ISICEM 2020, Brussels, Belgium.

16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definition conference. Crit Care Med. 2003;31:1250–6.

17. Faust JS, Weingart SD. The Past, Present, and Future of the Centers for Medicare and Medicaid Services Quality Measure SEP-1: The Early Management Bundle for Severe Sepsis/Septic Shock. Emerg Med Clin North Am. 2017;35:219-31.

18. Rhee C, Chiotos K, Cosgrove SE, Heil EL, Kadri SS, Kalil AC, et al. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clin Infect Dis. 2020;72:ciaa059.

19. Gallagher EJ. Clinical utility of likelihood ratios. Ann Emerg Med. 1998;31:391-7.

20. Parikh R, Parikh S, Arun E, Thomas R. Likelihood ratios: clinical application in day-to-day practice. Indian J Ophthalmol. 2009;57:217-21.

21. Lopansri BK, Miller RR III, Burke JP, Levy M, Opal S, Rothman RE, et al. Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort. J Intensive Care. 2019;7:13.

22. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45:486-552.

23. Swenson KE, Winslow DL. Impact of Sepsis Mandates on Sepsis Care: Unintended Consequences. J Infect Dis. 2020;222:S166–S173.

24. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49:e1063-e1143.

25. Zimmerman JJ, Sullivan E, Yager TD, Cheng C, Permut L, Cermelli S, et al. Diagnostic Accuracy of a Host Gene Expression Signature That Discriminates Clinical Severe Sepsis Syndrome and Infection-Negative Systemic Inflammation Among Critically Ill Children. Crit Care Med. 2017;45:e418–e425.

26. Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. Nat Med. 2020;26:333–40.

27. Deis, A. S., Whiles, B. B., Brown, A. R., Satterwhite, C. L. & Simpson, S. Q. Three-Hour Bundle Compliance and Outcomes in Patients With Undiagnosed Severe Sepsis. Chest. 2018;153:39–45.

28. Leisman DE, Doerfler ME, Ward MF, Masick KD, Wie BJ, Gribben JL, et al. Survival Benefit and Cost Savings From Compliance With a Simplified 3-Hour Sepsis Bundle in a Series of Prospective, Multisite, Observational Cohorts. Crit Care Med. 2017;45:395-406.

FIGURE LEGENDS

Figure 1. Correlation plot for SeptiCyte LAB vs. SeptiCyte RAPID. The scores for SeptiCyte RAPID (2 gene assay, x-axis scale 0-15) and SeptiCyte LAB (4 gene assay, x-axis scale 0-10) were measured for 356 patients from retrospective clinical trials performed in the USA (VENUS study) and Europe (MARS study). A least-squares linear fit to the data points ($y = -0.48 + 0.82x$) had Pearson's sample correlation coefficient $r = 0.88$.

Figure 2. Diagnostic performance of SeptiCyte RAPID. ROC curve analyses for SeptiCyte RAPID were performed using three different RPD methods (consensus, forced and unanimous), for either the full cohort (retrospective and prospective patients) or the prospective cohort. DeLong's test was used to determine if differences between curves were statistically significant. **(A)** Full cohort ROC curves for forced (black), consensus (blue) and unanimous (red) RPD, with AUC = 0.82, 0.85 and 0.85 respectively. **(B)** Prospective cohort ROC curves for forced (black), consensus (blue) and unanimous (red) RPD, with AUC = 0.86, 0.90 and 0.95 respectively.

Figure 3. Probability of sepsis as a function of SeptiScore. **(A)** Cumulative distributions of the SeptiScore for SIRS patients (black) and sepsis patients (red), as evaluated by consensus RPD. **(B)** Basis of sliding window calculation of P(sepsis) across the 0-15 SeptiScore range. A sliding window was defined to be 3 score-units wide initially (from 0 to 3), and 2-score-units wide

thereafter. It was shifted in 1-unit increments. The number of sepsis and SIRS in each placement of the window was counted, and P(sepsis) calculated as N_{sepsis} / (N_{sepsis} + N_{SIRS}). **(C)** Probability of sepsis as function of SeptiScore, from the sliding window analysis. Key: black curve, forced RPD; blue curve, consensus RPD; red curve, unanimous RPD. **(D)** Division of SeptiScore range into four sepsis probability bands.

Figure 4. Comparison of sepsis probabilities per band for **(A)** SeptiCyte LAB (N=324), **(B)** SeptiCyte RAPID combined retrospective + prospective cohorts (N=378), **(C)** SeptiCyte RAPID retrospective cohort (N=324), and **(D)** SeptiCyte RAPID prospective cohort (N=54). Assignment of sepsis or SIRS was by consensus RPD. Subjects called "indeterminate" by consensus RPD are not included. The ratio to the right of each whisker (x:y) indicates the number of patients called as sepsis (x) or SIRS (y) in the associated SeptiScore band. The number above each whisker describes the percentage of sepsis calls in each band. The error bars represent the lower and upper bounds of the 80% confidence interval for the sample proportion, calculated using the exact bionomial formula.

Figure 5. Comparison of lactate, procalcitonin and SeptiScore, without or with additional clinical variables, for discrimination of sepsis vs. SIRS. **(A)** Data from the combined retrospective and prospective cohorts. **(B)** Data from just the prospective cohort. Area under curve (AUC) distributions are shown for all 32,767 possible logistic combinations of the following variables: age, race (African-American or not), sex, MAP max, T min, T max, HR min, HR max, WBC min, WBC max, glucose max, lactate, procalcitonin, SeptiScore, num.SIRS. (Abbreviations: MAP, mean arterial pressure; T, core body temperature; HR, heart rate; WBC, white blood cell count; num.SIRS, number of SIRS criteria met.) Performance was assessed

against consensus RPD. Key: grey vertical line, lactate alone; grey distribution, lactate combined with other clinical variables except SeptiScore or PCT; blue vertical line, PCT alone; blue distribution, PCT combined with other clinical variables except SeptiScore; red vertical line, SeptiScore alone; red distribution, SeptiScore combined with other clinical variables.

Figure 6. Sepsis probability trajectories for selected patients by sequential likelihood ratio analysis. Abbreviations: PCT, procalcitonin; Tmax, maximum body core temperature; WBC min, minimum white blood cell count; RR max, maximum respiratory rate; Num.SIRS, number of SIRS criteria met; MAP min, minimum value of mean arterial pressure. Details of the analysis are provided in the Supplementary Information, Section 12.

Table 1. Demographic characteristics of study population. There were 41 (9.8%) indeterminates by consensus RPD, which are not shown in this table or included in the p-value calculations. Student's t-test was used to calculate p-values for the indicated comparisons.

Parameter		**SIRS (N=224) (Consensus)**	**Sepsis (N=154) (Consensus)**	**p-value**
		N (%)	**N (%)**	
Age	Median (Interquartile range, IQR))	57 (42-69)	62 (49-71)	p = 0.016
Sex	Female	98 (58%)	71 (42%)	female vs. male p = 0.65
	Male	126 (60%)	83 (40%)	
Race / Ethnicity	Asian	10 (53%)	9 (47%)	white vs. non-white[1] p = 0.75
	Black (American or European of African descent)	65 (64%)	37 (36%)	
	Hispanic	11 (52%)	10 (48%)	white vs. black p = 0.39
	Other	1 (50%)	1 (50%)	
	Unknown	2 (50%)	2 (50%)	
	White	135 (59%)	95 (41%)	
Study Site	Europe (1 site)	76 (60%)	50 (40%)	Europe vs. USA p = 0.76
	United States (9 sites)	148 (59%)	104 (41%)	
Source of Admission	Emergency department	138 (59%)	95 (41%)	ED vs. ward p = 0.0026
	Post Anesthesia Unit or Post-Operating Room	34 (83%)	7 (17%)	
	ICU	7 (58%)	5 (42%)	(post-anaesthesia or post-op) vs. ward p < 0.00001
	ICU, other hospital	14 (54%)	12 (46%)	
	Coronary care facility (CCF)	4 (80%)	1 (20%)	
	Wards	13 (33%)	26 (67%)	ICU or CCF vs. ward p = 0.024
	Other	13 (62%)	8 (38%)	

[1]Hispanic grouped with non-white for this comparison

Table 2. Clinical characteristics of study population. Consensus RPD was used as the comparator. There were 41/419 (9.8%) indeterminates by consensus RPD, which are not shown in this table or included in the p-value calculations. For categorical variables, a chi-squared test was used to calculate p-values across the SIRS and sepsis categories, except when N<5 for one or both categories in which case a binomial exact test was used instead. For continuous variables, Welch's two sample t-test was used to calculate p-values across the SIRS and sepsis categories.

Category	**SIRS (n=224; 59.3%)**	**Sepsis (n=154; 40.7%)**	**p-value**
	N (%) or Median (IQR)	N (%) or Median (IQR)	
Culture results			
Blood (+/- Other)	2 (5.0%)	38 (95.0%)	2.7×10^{-12}
Urine (+/- Other)	3 (12.5%)	21 (87.5%)	3.1×10^{-6}
Blood + Urine (+/- Other) (double positive)	1 (9.1%)	10 (90.9%)	9.0×10^{-4}
Sputum (+/- Other)	17 (60.7%)	11 (39.3%)	0.88
Other culture*	5 (23.8%)	16 (76.2%)	9.3×10^{-4}
Viral positives / coinfections (by PCR)	8 (25.0%)	24 (75.0%)	7.8×10^{-5}
No culture data recorded**	201 (79.1%)	53 (20.9%)	1.2×10^{-10}
Presumed initial site of infection			
Pulmonary (N=71)	8 (14.3%)	48 (85.7%)	7.0×10^{-12}
Abdominal (N=27)	1 (3.7%)	26 (96.3%)	4.1×10^{-9}
Blood (N=14)	0 (0%)	14 (100%)	6.3×10^{-6}
Urinary Tract (N=25)	2 (8.0%)	23 (92.0%)	1.8×10^{-7}
Central Nervous System (N=9)	4 (44.4%)	5 (55.6%)	0.50
Other (N=16)	2 (12.5%)	14 (87.5%)	1.2×10^{-4}
Multiple (N=5)	0 (0%)	5 (100%)	0.011
Not Identified at Initial Evaluation (N=226)	207 (91.6%)	19 (8.4%)	$< 1 \times 10^{-15}$
Clinical parameters (Median, IQR)			
Minimum Temperature	36 (35.5-36.4)	36.1 (35.2-36.7)	0.9
Maximum Temperature	37.2 (36.9-37.8)	37.8 (37.2-38.6)	< 0.001

Category	**SIRS (n=224; 59.3%)**	**Sepsis (n=154; 40.7%)**	**p-value**
	N (%) or Median (IQR)	N (%) or Median (IQR)	
SOFA	6.0 (4.0-8.0)	7.0 (5.0-9.0)	0.004
Procalcitonin	0.28 (0.05-1.33)	5.19 (0.85-25.72)	$< 1 \times 10^{-5}$
WBC max (cells/uL x 10^{-3})	12.65 (8.3-17.20)	14.9 (9.94-21.15)	2×10^{-4}
Lactate	2.05 (1.40-3.28)	2.40 (1.55-4.05)	0.5
Interventions (Median, IQR)			
Invasive mechanical ventilation	86 (62.3%)	52 (37.7%)	0.47
Antibiotic administration	134 (47.3%)	149 (52.6%)	4.3×10^{-5}
Vasopressor Use	59 (46.5%)	68 (53.5%)	0.0032
Outcomes (Median, IQR)			
Hospital length of stay	4 (3-7)	8 (4-15)	< 0.001
ICU length of stay	1.8 (1.2-3.3)	3.2 (1.7-7.0)	< 0.001
Death	19 (8.5%)	22 (14.3%)	0.095
SeptiCyte RAPID Score *** (Median, IQR)	5.3 (4.6-6.3)	7.9 (6.8-9.6)	$< 1 \times 10^{-5}$

* Other culture includes the following sample types: bronchial combicath, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), pus, nares, stool, throat swab, drain fluid, body fluid, interstitial fluid, skin swab.

** including 7 positive blood cultures deemed to be false positives

*** Clinicians did not have access to SeptiCyte RAPID Scores during their clinical assessments of patients

Table 3. Interpretation of SeptiCyte RAPID scores. This table provides the performance metrics for SeptiScores falling within each band. The consensus RPD method was used as comparator in all analyses. Positive likelihood ratios were calculated as described in Supplementary Information, Section 12.

SeptiScore Band	Cohort	Average Probability		Sepsis Likelihood Ratio	Percentage of Cohort
		SIRS	Sepsis		
Band 4 (7.4 – 15) High Risk of Sepsis	Retrospective	20 (20%)	81 (80%)	5.89	31%
	Prospective	3 (17%)	15 (83%)	7.27	33%
	Combined	23 (19%)	96 (81%)	6.07	32%
	SeptiCyte LAB	20 (21%)	75 (79%)	5.45	29%
Band 3 (6.2 – 7.3)	Retrospective	34 (58%)	25 (42%)	1.07	18%
	Prospective	7 (58%)	5 (42%)	1.04	22%
	Combined	41 (58%)	30 (42%)	1.06	19%
	SeptiCyte LAB	43 (56%)	34 (44%)	1.15	24%
Band 2 (5.0 – 6.1)	Retrospective	60 (78%)	17 (22%)	0.41	24%
	Prospective	13 (87%)	2 (13%)	0.22	28%
	Combined	73 (79%)	19 (21%)	0.38	24%
	SeptiCyte LAB	70 (80%)	18 (20%)	0.37	27%
Band 1 (0 – 4.9) Low Risk of Sepsis	Retrospective	78 (90%)	9 (10%)	0.17	27%
	Prospective	9 (100%)	0 (0%)	0.00	17%
	Combined	87 (91%)	9 (9%)	0.15	25%
	SeptiCyte LAB	59 (92%)	5 (8%)	0.12	20%

Table 4. Characteristics of all patients stratified by RPD, demographic and clinical parameters, and SeptiScore band. A chi-squared test or ANOVA was used, for categorical variables or continuous variables, respectively, to calculate p-values across or within the SeptiScore bands as appropriate. In the chi-squared analyses, p(Bi, i=1…4) means the probability of the observed vs. expected distributions of patients across sub-categories (e.g. male, female; or Black, White, Other) within band Bi.

Category	**Subcategory**	**SeptiScore 0-4.9 (Band B1) (N=104; 24.8%)**	**SeptiScore 5-6.1 (Band B2) (N=103; 24.6%)**	**SeptiScore 6.2-7.3 (Band B3) (N=82; 19.6%)**	**SeptiScore 7.4-15 (Band B4) (N=130; 31.0%)**	**Significance**
RPD Process						
RPD: Consensus (sepsis+SIRS = 378)	Indeterminate (N=41; 9.8%)	8 (7.7%)	11 (10.7%)	11 (13.4%)	11 (8.5%)	p(B1,B2,B3,B4) = 1.6×10^{-9}, 4.7×10^{-4}, 0.53, $<1.0 \times 10^{-15}$
	Sepsis (N=154; 36.8%)	9 (8.6%)	19 (18.4%)	30 (36.6%)	96 (73.8%)	
	SIRS (N=224; 53.5%)	87 (83.6%)	73 (70.9%)	41 (50.0%)	23 (17.7%)	
RPD: Forced (sepsis+SIRS = 419)	Sepsis (N=176; 42.0%)	13 (12.5%)	23 (22.3%)	37 (45.1%)	103 (79.2%)	p(B1,B2,B3,B4) = 1.1×10^{-9}, 5.2×10^{-5}, 0.57, $<1.0 \times 10^{-15}$
	SIRS (N=243; 58.0%)	91 (87.5%)	80 (77.7%)	45 (54.9%)	27 (20.8%)	
RPD: Unanimous (sepsis+SIRS = 276)	Sepsis (N=119; 28.4%)	7 (6.7%)	12 (11.6%)	23 (28.0%)	77 (59.2%)	p(B1,B2,B3,B4) = 6.3×10^{-7}, 6.0×10^{-4}, 0.97, 3.2×10^{-15}
	SIRS (N=157; 37.5%)	60 (57.7%)	51 (49.5%)	30 (36.6%)	16 (12.3%)	
	N/A (N=143; 34.1%)	37 (35.6%)	40 (38.8%)	29 (35.4%)	37 (28.5%)	
Demographics						
Age	Median, (Q1-Q3)	56.5 (42.8-68.2)	59 (44.5-69)	58 (41.2-74)	62 (48.2-70)	p = 0.59
Sex	female (N=187; 44.6%)	46 (44.2%)	41 (39.8%)	37 (45.1%)	63 (48.5%)	p(B1,B2,B3,B4) = 0.93, 0.33, 0.92, 0.38
	male (N=232; 55.4%)	58 (55.8%)	62 (60.2%)	45 (54.9%)	67 (51.5%)	
Race	Black (N=115; 27.4%)	25 (24.0%)	33 (32.0%)	21 (25.6%)	36 (27.7%)	p(B1,B2,B3,B4) = 0.70, 0.22, 0.20, 0.92
	White (N=254; 60.6%)	65 (62.5%)	63 (61.2%)	46 (56.1%)	80 (61.5%)	
	Other (N=50; 11.9%)	14 (13.5%)	7 (6.8%)	15 (18.3%)	14 (10.8%)	
Culture Results*						
Blood (+/- secondary)	Number (%) positive (out of 41)	1 (2.4%)	6 (14.6%)	8 (19.5%)	26 (63.4%)	$p = 7.0 \times 10^{-5}$
Urine (+/- secondary)	Number (%) positive (out of 25)	5 (20.0%)	4 (16.0%)	3 (12.0%)	13 (52.0%)	p = 0.15
Blood + Urine (+/- tertiary)	Number (%) double positive (out of 11)	0 (0.0%)	2 (18.2%)	1 (9.1%)	8 (72.7%)	p = 0.018

Category	**Subcategory**	**SeptiScore 0-4.9 (Band B1) (N=104; 24.8%)**	**SeptiScore 5-6.1 (Band B2) (N=103; 24.6%)**	**SeptiScore 6.2-7.3 (Band B3) (N=82; 19.6%)**	**SeptiScore 7.4-15 (Band B4) (N=130; 31.0%)**	**Significance**
Sputum (+/- secondary)	Number (%) positive (out of 31)	7 (22.6%)	1 (3.2%)	9 (29.0%)	14 (45.2%)	p = 0.026
Other culture**	Number (%) positive (out of 24)	4 (16.7%)	3 (12.5%)	7 (29.2%)	10 (41.7%)	p = 0.26
No culture data recorded ***	Number (%) without data (out of 287)	87 (30.3%)	85 (29.6%)	56 (19.5%)	59 (20.6%)	p = 8.7 x 10^{-4}
Presumed Initial Site of Infection*						
Pulmonary	Number (%) out of 71	6 (8.5%)	11 (15.5%)	16 (22.5%)	38 (53.5%)	p = 6.6 x 10^{-5}
Abdominal	Number (%) out of 33	2 (6.1%)	6 (18.2%)	6 (18.2%)	19 (57.6%)	p = 0.005
Blood	Number (%) out of 15	1 (6.7%)	1 (6.7%)	3 (20.0%)	10 (66.7%)	p = 0.016
Urinary Tract	Number (%) out of 26	3 (11.5%)	5 (19.2%)	2 (7.7%)	16 (61.5%)	p = 0.0073
Central Nervous System	Number (%) out of 11	2 (18.2%)	2 (18.2%)	3 (27.3%)	4 (36.4%)	p = 0.85
Other	Number (%) out of 17	1 (5.9%)	1 (5.9%)	7 (41.2%)	8 (47.1%)	p = 0.014
Multiple	Number (%) out of 5	0 (0.0%)	2 (40.0%)	0 (0.0%)	3 (60.0%)	p = 0.24
Not Identified at Initial Evaluation	Number (%) out of 241	89 (36.9%)	75 (31.1%)	45 (18.7%)	32 (13.3%)	p = 2.5 x 10^{-9}
Clinical Parameters						
Temperature (Min)	Median, (Q1-Q3)	36.0 (35.2-36.4)	36.2 (35.6-36.6)	36.2 (35.5-36.7)	36.0 (35.4-36.7)	p = 0.2
Temperature (Max)	Median, (Q1-Q3)	37.2 (37.0-37.8)	37.3 (36.8-37.9)	37.4 (36.9-38.2)	37.8 (37.2-38.4)	p < 0.001
Lactate	Median, (Q1-Q3)	1.9 (1.3-3.3)	2.1 (1.6-3.3)	2.2 (1.5-3.3)	2.6 (1.6-4.1)	p = 0.69
WBC.Max	Median, (Q1-Q3)	13.5 (8.5-17.2)	12.2 (8.4-17.4)	13.9 (10.2-17.9)	14.6 (9.0-21.1)	p = 0.017
Procalcitonin	Median, (Q1, Q3)	0.3 (0.05-0.9)	0.3 (0.05-1.1)	0.6 (0.16-2.6)	5.6 (1.7-25.8)	p < 1 x 10^{-5}
SeptiScore	Median, (Q1-Q3)	4.4 (3.8-4.7)	5.6 (5.3-5.8)	6.8 (6.5-7.0)	8.7 (8.0-10.1)	p < 1 x 10^{-5}

* If small sample size (<5) in one or more categories, implying an increased uncertainty in the quantitative value of p, then calculation of p was performed by Monte Carlo simulation-based method [see https://www.statskingdom.com/310GoodnessChi.html for applet and R code].

** “Other culture” includes the following sample types: bronchial combicath, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), pus, nares, stool, throat swab, drain fluid, body fluid, interstitial fluid, skin

*** including 7 blood culture false positives

Table 5. Sequential Likelihood Ratio calculations for six example patients. The pre-test probability of sepsis is computed as the fraction of all patients called septic under forced RPD (176/419 = 0.42). The post-test probability of sepsis was computed either after incorporation of the SeptiCyte RAPID data, or after incorporation of the logistic regression formula which uses the data from SeptiCyte RAPID, PCT, Temp max, WBC min, Respiratory Rate max, Mean Arterial Pressure min, and # (SIRS characteristics). Additional details of the calculation are given in Supplementary Information, Section 12.

Patient	Forced RPD	SeptiScore	SeptiCyte RAPID Band	pre-test probability of sepsis	post-SeptiCyte RAPID probability of sepsis	post-logistic regression probability of sepsis
A	sepsis	10	4	0.42	0.947	0.98
B	sepsis	8.7	4	0.42	0.838	0.98
C	sepsis	7.5	4	0.42	0.641	0.901
D	SIRS	5.2	2	0.42	0.249	0.176
E	SIRS	4.6	1	0.42	0.186	0.127
F	SIRS	3.4	1	0.42	0.106	0.083

FIGURE 1


10.0
7.5
5.0
2.5
0.0
SeptiCyte LAB score
2.5
5.0
7.5
10.0
12.5
15.0
SeptiCyte RAPID score

FIGURE 2


A
Retrospective cohort
true positive fraction
false positive fraction
B
Prospective cohort
true positive fraction
false positive fraction
C
Combined cohort
true positive fraction
false positive fraction
D
6.6
specificity
sensitivity
value
threshold

FIGURE 3


A
consensus RPD
SIRS
sepsis
cumulative %
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
0
2.5
5
7.5
10
12.5
15
RAPID Score
B
C
consensus RPD
forced RPD
unanimous RPD
sepsis probability
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0
3
6
9
12
15
RAPID Score
D
SeptiScore increases with probability of sepsis
0
15
SIRS
SEPSIS
BAND 1
BAND 2
BAND 3
BAND 4
5.0
6.2
7.4

FIGURE 4


A SeptiCyte LAB
B SeptiCyte RAPID
C SeptiCyte RAPID retrospective
D SeptiCyte RAPID prospective
Sepsis Probability
1.00
0.75
0.50
0.25
0.00
Band 1
Band 2
Band 3
Band 4
7.8 %
5:59
20.5 %
18:70
44.2 %
34:43
78.9 %
75:20
9.4 %
9:87
20.7 %
19:73
42.3 %
30:41
80.7 %
96:23
10.3 %
9:78
22.1 %
17:60
42.4 %
25:34
80.2 %
81:20
0 %
0:9
13.3 %
2:13
41.7 %
5:7
83.3 %
15:3

FIGURE 5


A
Lactate
PCT
SeptiScore
count
600
400
200
0
0.5
0.6
0.7
0.8
0.9
1.0
AUC
B
Lactate
PCT
SeptiScore
count
3000
2000
1000
0
0.5
0.6
0.7
0.8
0.9
1.0
AUC

FIGURE 6


1.0
0.8
0.6
0.4
0.2
0.0
probability of sepsis
patient A
patient B
patient C
patient D
patient E
patient F
pre-test
+ SeptiScore
+ SeptiScore
+ log2 (PCT)
+ Tmax
+ WBC min
+ RR max
+ Num.SIRS
+ MAP min

.